Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eganelisib - Infinity Pharmaceuticals

Next Previous
Drug Profile

Eganelisib - Infinity Pharmaceuticals

Alternative Names: IPI-549

Latest Information Update: 04 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intellikine
  • Developer Arcus Biosciences; Bristol-Myers Squibb; Infinity Pharmaceuticals; University of California, San Diego
  • Class Amides; Amines; Antineoplastics; Isoquinolines; Pyrazoles; Pyrazolones; Pyrimidines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase gamma inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer; Urogenital cancer

Most Recent Events

  • 03 Mar 2026 Stelexis BioSciences plans a phase I GAVEL trial for Acute myeloid leukemia (Combination therapy) in USA in July 2026 (NCT07439211)
  • 25 Jul 2025 The University of California, San Diego, in collaboration with the V Foundation for Cancer Researchcompletes a phase-II clinical trials in Head and neck cancer (Late-stage disease) in USA (PO) (NCT03795610)
  • 06 Aug 2024 Stelexis BioSciences plans a phase Ib trial for Acute myeloid leukemia (Monotherapy, Combination Therapy) (PO) in January 2025 (NCT06533761)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top